anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fibrosis is a prevailing pathology in chronic diseases and accounts for 45% of deaths in developed countries. This condition is primarily identified by the transformation of fibroblasts into myofibroblasts and the overproduction of extracellular matrix (ECM) by myofibroblasts. Pterostilbene (PTS) is a natural analogue of resveratrol and is most commonly found in blueberries. Research has shown that PTS exerts a wide range of pharmacological effects, such as antioxidant, anti-inflammatory, and anticancer effects. As a result, PTS has the potential to prevent and cure numerous diseases. Emerging evidence has indicated that PTS can alleviate myocardial fibrosis, renal fibrosis, pulmonary fibrosis, hepatic fibrosis, and colon fibrosis via the inhibition of inflammation, oxidative stress, and fibrogenesis effects in vivo and in vitro, and the potential mechanisms are linked to various pathways, including transforming growth factor-β1 (TGF-β1)/small mother against decapentaplegic proteins (Smads) signalling, the reactive oxygen species (ROS)-driven Pitx2c/mir-15b pathway, nuclear factor kappa B (NF-κB) signalling, Kelch-like epichlorohydrin-associated protein-1 (Keap-1)/NF-E2-related factor-2 (Nrf2) cascade, the NLR family pyridine structure domain 3 (NLRP3) pathway, the Janus kinase-2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway, and the Src/STAT3 pathway. In this review, we comprehensively summarize the antifibrotic effects of PTS both in vivo and in vitro and the pharmacological mechanisms, pharmacokinetics, and toxicology of PTS and provide insights into and strategies for exploring promising agents for the treatment of fibrosis.
The present invention relates to an externally pasted plaster for treating wind-cold knee joint pain, which has the components of 50 to 100g of radix aconite, 50 to 120g of Chinese ephedra, 50 to 100g of cinnamon, 50 to 100g of nux vomica, 50 to 100g of frankincense, 50 to 100g of myrrh, 50 to 100g of honeycomb of paper wasp and 10 to 50g of centipede, wherein all of the components are raw and crude; the radix aconite and the nux vomica are crushed; the honeycomb of paper wasp, the Chinese ephedra and the centipede are cut into small segments; the radix aconite, the nux vomica, the honeycomb of paper wasp, the Chinese ephedra and the centipede are soaked in bean oil for three to ten days and are poured into an iron pan to be decocted by soft wire until the medicine becomes withered and the oil becomes black. After the medicine is filtered, the yellow lead is added to the medicine. After the medicine is decocted, the fine powder of the cinnamon, the frankincense and the myrrh is put into the paste of which the oil is warm. The plaster is stirred uniformly and is poured into a cold water basin to be soaked for three days. The plaster is fetched out and is sealed for standby. When used, the plaster is externally pasted on two acupuncture points of xiyan and dubi. The plaster is changed once every seven days, and three times form one course of treatment. The preparation method of the present invention is reasonable, and the plaster of the present invention has conspicuous curative effects and high recovery rates.
The present invention relates to vitiligo removing tincture for treating vitiligo and a preparing method thereof. The vitiligo removing tincture for treating vitiligo is characterized in that the vitiligo removing tincture for treating vitiligo comprises the medical materials of the following weight: 21 g of ginseng, 24 g of astragalus root, 35 g of prepared fleeceflower root, 24 g of rehmanniae, 28 g of glossy privet fruit, 28 g of densefruit pittany root-bark, 35 g of difengpi bark and 14 g of obscured homalomena rhizome. The 8 medical materials are pulverized into coarse powder, according to a percolation method of an extract and a liquid extract, ethanol is used as solvent, percolation is carried out after immersion, percolation liquid is collected, a standing process and a filtering process are carried out, and then the vitiligo removing tincture for treating vitiligo is obtained by adding the ethanol and stirring. The present invention conforms to a theory method of a Chinese medicine theory, has a reasonable prescription and carries out symptom and sign differentiation treatment, and the medicine of the whole prescription is recorded in the herb works of physicians over the ages and the Chinese medicine works of modern ages. The medicine of the present invention has no obviously toxic side effect and conforms to a safe and effective medical taking principle. The vitiligo removing tincture has good treating effect on various kinds of vitiligo of topical type, symmetry type, common type, scattering type, nerve segment type, etc., and the total effective rate of the vitiligo removing tincture reaches 86.7%.
All patients within a given cohort will be treated with the same dose schedule of TG6002, administred as 3 weekly IV infusions at days 1, 8 and 15. following the 1st and 2nd infusions of TG6002, patients will be given oral 5-FC for 3 days starting on day 5 and 12 . following the 3rd infusion, patients will be given oral 5-FC for 21 days starting on day 19.
Embodiments of an apparatus, system and method for facilitating the tracking of consumable pharmaceutical articles are disclosed. A marking apparatus is configured to apply unique indelible identifiers to pharmaceutical articles at the point-of-sale. The indelible identifiers on the articles are visually or electronically readable to allow each respective article to be traced with respect to its manufacturer, prescribing physician, patient to whom it was prescribed, dispensing location, expiration date, dosage, or some combination thereof. An associated system and method may involve the provision of a remote database element configured to be in network communication between the marking apparatus, manufacturer, distributor, prescriber, dispensing location, scanning tool, or some combination thereof. The indelible identifier may initially be generated by the apparatus and then obtained and recorded by the remote database element. Alternative, the indelible identifier may initially be generated and recorded by the remote database element, then provided to the marking apparatus.
A composition for the preservation of foodstuffs, for the sterilization of air in confined spaces and for cosmetic and pharmaceutical purposes comprising an essential oil having bacteriostatic and/or bactericidal properties or a bacteriostatically and/or bactericidally active compound extracted from such an oil, acetic or citric acid and ethanol or ispropyl alcohol.  The composition may comprise oil of cloves, cinnamon oil, peppermint oil, oil of thyme, oil of rosemary, mustard oil, thymol, cinnamic aldehyde, polyoxyethylene oleate or stearate, polyoxyethylene sorbitan mono-palmitate, mono- or tri-oleate, or mono- or tri-stearate, and mucilages of animal, vegetable or synthetic origin (e.g. tragacanth or agar-agar). The composition may be in the form of an aqueous concentrate.  The composition may be applied to the food by steeping or spraying. Sheep's guts, pigs' intestines, fish, shellfish, sausages, cheese and pastry goods may be treated.  The composition may be sprayed or vapourized in room to sterilize it. The composition may be used for the prevention of body odour, skin care, and the treatment of colds.ALSO:A composition for the preservation of foodstuffs, for the sterilisation of air in confined spaces and for cosmetic and pharmaceutical purposes comprising an essential oil having bacteriostatic and/or bactericidal properties or a bacteriostatically and/or bactericidally active compound extracted from such an oil acetic or citric acid and ethanol or isopropyl alcohol.  The composition may comprise oil of cloves, cinnammon oil, peppermint oil, oil of thyme, oil of rosemary, mustard oil, thymol, cinnamic aldehyde, polyoxyethylene oleate or stearate, polyoxyethylene sorbitan mono - palmitate, mono- or tri-oleate, or mono- or tri-stearate, and mucilages of animal, vegetable or synthetic origin (e.g. tragacanth or agar-agar).  The composition may be in the form of an aqueous concentrate.  The composition may be applied to the food by steeping or spraying.  Sheep's guts, pigs intestines, fish, shellfish, sausages, cheese and pastry goods may be treated.  The composition may be sprayed or vapourised in a room to sterilise it.  The composition may be used for the prevention of body odour, skin care, and the treatment of colds.
The Specific Therapy Program for Personality Disorders at the 1st Psychiatric Clinic, Medical School, National and Kapodistrian University of Athens, Eginition Hospital, established in 1999, offers outpatient, inpatient, and day care services with psychoanalytic interventions tailored for Borderline Personality Disorder. Group psychoanalytic psychotherapy sessions are predominant, supported by research. Patients undergo initial 6-8 months of closely monitored outpatient care, including monthly psychodynamically oriented sessions, psychiatric appointments, and psychological assessments, focusing on crisis management and personalized treatment plans. Subsequently, long-term psychodynamic psychotherapy interventions, often combined with psychiatric treatment, provide sustained therapeutic support.
FIELD: medicine. ^ SUBSTANCE: invention concerns photodynamic therapy (PDT) and claims composition with low concentration of hydrophobic photosensibilisers (PS) and improved method of PDT. In the claimed composition, given PS, meta-tetrahydroxyphenylchlorine (m-THPC) is present in concentration of 0.8 mg/ml to 0.04 mg/ml in the mix of pure ethyleneglycol and ethanol at 3:2 ratio. Composition reduces therapeutic effect accumulation time for the PS in affected tissue and time of achieving sufficient PS ratio in comparison to healthy tissue. Application of composition with m-THPC PS reduces interval between PS application/injection and irradiation. PS diffusion between affected and normal tissues can proceed fast enough for introduction in 'one day' or one night time. Claimed composition can be applied for PDT regimens where photosensibilisers are introduced in at least one prearranged dosage, including low-concentration therapy for PDT. ^ EFFECT: enhanced precision, effect and convenience dosage due to application of the claimed composition with low concentration in PDT. ^ 7 cl, 2 ex, 4 tbl
Objective: In chronic hepatitis B (CHB) patients with previous 96-week treatment with tenofovir amibufenamide (TMF) or tenofovir disoproxil fumarate (TDF), we investigated the safety profile of sequential TMF treatment from 96 to 144 weeks. Methods: Enrolled subjects that previously assigned (2:1) to receive either 25 mg TMF or 300 mg TDF with matching placebo for 96 weeks received extending or switching TMF treatment for 48 weeks. Safety profiles of kidney, bone, metabolism, body weight, and others were evaluated. Results: 666 subjects from the initial TMF group and 336 subjects from TDF group with at least one dose of assigned treatment were included at week 144. The overall safety profile was favorable in each group and generally similar between extended or switched TMF treatments from week 96 to 144. In subjects switching from TDF to TMF, the non-indexed estimated glomerular filtration rate (by non-indexed CKD-EPI formula) and creatinine clearance (by Cockcroft-Gault formula) were both increased, which were (2.31±8.33) ml/min and (4.24±13.94) ml/min, respectively. These changes were also higher than those in subjects with extending TMF treatment [(0.91±8.06) ml/min and (1.30±13.94) ml/min]. Meanwhile, switching to TMF also led to an increase of the bone mineral density (BMD) by 0.75% in hip and 1.41% in spine. On the other side, a slight change in TC/HDL ratio by 0.16 (IQR: 0.00, 0.43) and an increase in body mass index (BMI) by (0.54±0.98) kg/m2 were oberved with patients switched to TMF, which were significantly higher than that in TMF group. Conclusion: CHB patients receiving 144 weeks of TMF treatment showed favorable safety profile. After switching to TMF, the bone and renal safety was significantly improved in TDF group, though experienceing change in metabolic parameters and weight gain (NCT03903796).
Poor oral health conditions in adults are associated with chronic pain. A nationwide cross-sectional study was conducted to investigate the link between tooth loss and chronic pain. The study involved 8,662 participants from the National Health and Nutrition Examination Survey. Tooth count was categorized into 4 groups, and chronic pain was defined as persistent pain lasting over 3 months despite treatment. Location of the chronic pain, demographics, comorbidities, lifestyle determinants, and dietary intake were retrieved. Univariate and multivariate logistic regression were used to explore cross-sectional associations between tooth count and chronic pain. Compared to participants with more than 20 teeth, those with severe tooth loss presented greater odds of chronic pain (adjusted odds ratio [aOR] = 2.111, 95% confidence intervals (CI) = 1.213-3.676 for patients with 1-8 teeth). Edentulous participants presented with significantly higher odds of chronic pain in the lower extremities (78.4%) and buttocks (49.5%). In the multivariate model, apart from rheumatic arthritis (aOR = 4.004, 95% CI = 2.766-5.798), variables of higher chronic pain included smoking (aOR = 1.518, 95% CI = 1.228-1.878), and hypertension (aOR = 1.463, 95% CI = 1.013-2.112). On the contrary, being Mexican American (aOR = .603, 95% CI = .414-.880) was associated with lower odds of chronic pain. The findings suggested a significant link between chronic pain and tooth loss, independent of ethnicity, lifestyle determinants, and immune-mediated inflammatory diseases including rheumatoid arthritis. PERSPECTIVE: A U.S. nationwide study examined tooth loss and chronic pain. Those with severe tooth loss had increased odds of chronic pain. Edentulous individuals presented higher odds of pain in lower extremities and buttocks. This study highlighted the link between tooth loss and chronic pain, independent of comorbidities and lifestyle factors.
PROBLEM TO BE SOLVED: To obtain the objective compound expressing remarkable fibroblast proliferation promoting action and no cytotoxicity, safe for human and animal and useful as an external skin agent and a bath material by using an extract of a specific material derived from a plant base. SOLUTION: This fibroblast proliferation promoter containing a water extract from chlorella uses the water extract of chlorella as an effective ingredient. Chlorella is unicellular green algae having 3-10 micron diameter and classified to the division Chlorophyta, the class Chlorophyceae, the order Chlorococcales, the family Oocystaceae and the genus Chlorella. The water extract of chlorella is made by extracting chlorella itself or dried one with water or hot water. When the water extract of chlorella is used as a skin preparation for external use and a bath material, the amount to be used is 0.0005wt.%, preferably about 3-40wt.%. The skin preparation for external use and the bath material containing the chlorella extract can be used for the skin and the head area to prevent and improve inflammation caused by eczema, itching, skin drying, skin chapping, etc.
In the present invention, there is disclosed a pyrazole derivative of the general formula I, in which Re1 denotes hydrogen, cycloalkyl containing 1 to 7 carbon atoms or –ORe7, wherein alkyl having 1 to 6 carbon atoms and cycloalkyl containing 3 to 7 carbon atoms can optionally be substituted; Re2 represents hydrogen, alkyl having 1 to 6 carbon atoms, alkenyl containing 3 to 6 carbon atoms or Re9 through Re4 have specific meanings. Disclosed are also processes for preparing the above-indicated compound as well as intermediates used in the preparation thereof. Further disclosed is a pharmaceutical composition based on the above-described compounds as well as the use of the compounds. The above-indicated compounds bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodeficiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to agents used for treatment of fungal diseases. Invention provides the development of solid medicinal form of terbinafine hydrochloride containing active substance, filling agents, wetting agent, powdering agent and preserving agent taken in the ratio given in the invention claim. Invention provides the use of less deficient and more available components and decrease of the preparation price. EFFECT: improved properties of agent, decreased cost. 2 tbl, 9 ex
PURPOSE:To provide the titled emulsion preparation useful as an erythrocyte substitute for mammals and perfusion liquid for the storage of organs in organ transplantation, storable stably for a long period, and excreted easily from the body, by using a specific perfluoro-compound as an oxygen carrier component. CONSTITUTION:The objective O/W-type emulsion is prepared by dispersing the compound of formula (R is perfluoromethyl or perfluoroethyl), e.g. perfluoro-4- methyloctahydroquinolidine, as an oxygen carrier component, in a physiological saline water, lactated Ringer's solution, etc. using a polymeric nonionic surface active agent (molecular weight: 2,000-20,000) as an emulsifier. The amount of the compound of formula is 5-50W/V%, preferably 10-40W/V%, and that of the emulsifier is 1-5W/V%. The components are mixed together in arbitrary order to obtain a course emulsion, which is homogenized with a proper homogenizer to a particle size of <=0.3mu, preferably <=0.2mu.
OBJECTIVES: To study the impact of a restrictive calcium replacement protocol in comparison with a liberal one in patients with septic shock.
MATERIAL AND METHODS: Multicenter retrospective before-after study that estimated the impact of implementing a restrictive calcium replacement protocol in patients with septic shock. Patients admitted to an intensive care unit between May 2019 and April 2021 were assigned to liberal calcium replacement, and those admitted between May 2021 and April 2022 were assigned to a restrictive protocol. The primary outcome measure was 28-day mortality. Patients were matched with propensity scores.
RESULTS: A total of 644 patients were included; liberal replacement was used in 453 patients and the restrictive replacement in 191. We paired 553 patients according to propensity scores, 386 in the liberal group and 167 in the restrictive group. Mortality did not differ significantly between the groups at 28 days (35.3% vs 32.3%, respectively; hazard ratio, 0.97; 95% CI, 0.72-1.29) or after resolution of septic shock (81.5% vs 83.8%; hazard ratio, 0.89; 95% CI, 0.73-1.09). Nor did scores on the Sepsis-related Organ Failure Assessment scale differ (2.1 vs 2.6; P = 0.20).
CONCLUSION: The implementation of a restrictive calcium replacement protocol in patients with septic shock was not associated with a decrease in 28-day mortality in comparison with use of a liberal protocol. However, we were able to reduce calcium replacement without adverse effects.
Background and Objectives: The Walking Impairment Questionnaire (WIQ) is a short and simple tool to measure walking impairment for patients with peripheral arterial disease requiring no special equipment or trained staff. The aim of this study was to assess the validity and reliability of the culturally adapted Lithuanian WIQ version in patients with intermittent claudication. Materials and Methods: In total, 40 patients with intermittent claudication and ankle-brachial index < 0.90 participated in this study. Reliability and internal consistency of the questionnaire were assessed by the intra-class correlation coefficient (ICC) and Cronbach's alpha (α), respectively. Validity was determined by correlations between the WIQ scores and a subjective test (Quality of Life 5 Dimension Questionnaire 3 Level Version (EQ-5D-3L)) and objective tests (6 min walk test (6MWT), treadmill test, and ankle-brachial index). Results: The test-retest reliability was assessed as excellent with an intraclass correlation coefficient of 0.90. The values of Cronbach's alpha were 0.957 (I time) and 0.948 (II time) and indicated an excellent internal consistency. Statistically significant Spearman correlations were detected between the WIQ and walking distances on the 6MWT (rho 0.514, p < 0.001) and treadmill test (rho 0.515, p < 0.001). Higher WIQ scores were associated with longer walking distances and duration. Moderate negative and low negative correlations were found between the WIQ and EQ-5D-3L scores. Conclusions: The Lithuanian version of culturally adapted WIQ demonstrates reliability and validity for patients with intermittent claudication, supported by two different walking tests showing statistically significant moderate Spearman correlations.
INTRODUCTION: The craniovertebral junction (CVJ) is susceptible to diverse pathologies. While the transoral-transpharyngeal approach has been the primary method for addressing anterior CVJ conditions, it carries significant morbidity. Endoscopic endonasal approach (EEA), has emerged as a Minimally invasive option. However, EEA has potential limitations in providing adequate caudal exposure. This study aims to evaluate the feasibility of enhancing caudal exposure to the endoscopic transodontoid (TO) approach by drilling the posterior part of the central hard palate, thus achieving an extended endoscopic approach to odontoid (ETO) and to compare the accuracy of predictive lines, (Nasopalatine line (NPL), Nasoaxial line (NAxL), and Rhinopalatine line (RPL)) in predicting the caudal limit of the approach.
METHODS: Eight cadaveric specimens underwent pre and post-endoscopic dissection measurements. The distance resected (DR), and inferior exposure of C2 posterior wall (PW) were measured and compared between TO and ETO. Furthermore, multivariable logistic regression was utilized to assess the predictive line values for DR.
RESULTS: Implementation of the ETO resulted in a significant increase in mean DR (8.6 mm, 52% improvement, p-value 0.03381), and the inferior exposure of the PW increased by 5.31 mm (p-value 6.063e-05, 37% greater exposure). The linear multivariable regression analysis indicated significant positive associations between NAxL, RPL and DR after TO. However, these associations were not seen for ETO.
CONCLUSION: The ETO proved superior to the traditional approach, providing improved caudal exposure and distance resected. While NPL and NAxL demonstrated predictive value for the TO, their utility was somewhat limited in the ETO.
FIELD: medicine, hematology. SUBSTANCE: invention relates to methods of correction of blood ionic composition, mainly to Na + ,Ca 2+ ,K + ,Mg 2+  at damage of ion concentrations. Method involves intranasal administration of the correcting mixture consisting of Samokhotsky's standard and a preparation based on bee honey - vitamedin at volume ratio from 1:1000 to 1:10. Samokhotsky's standard is an aqueous solution of the definite composition containing Na + ,K + ,Ca 2+  or Mg 2+  bichromates, respectively. Use of this mixture provides the synergetic effect of components that ensures to obtain remission of chronic diseases accompanying with disorder of blood ionic composition. EFFECT: improved total body state. 1 tbl, 3 ex